Gene Therapy Market Size, Share, and Trends 2024 to 2034

The global gene therapy market size is calculated at USD 11.07 billion in 2025 and is forecasted to reach around USD 55.43 billion by 2034, accelerating at a CAGR of 19.60% from 2025 to 2034. The North America gene therapy market size surpassed USD 5 billion in 2024 and is expanding at a CAGR of 19.62% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.

  • Last Updated : February 2025
  • Report Code : 1462
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Gene Therapy Market 

5.1. COVID-19 Landscape: Gene Therapy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Gene Therapy Market, By Type

8.1. Gene Therapy Market, by Type

8.1.1. Gene Silencing

8.1.1.1. Market Revenue and Forecast

8.1.2. Cell Replacement

8.1.2.1. Market Revenue and Forecast

8.1.3. Gene Augmentation

8.1.3.1. Market Revenue and Forecast

8.1.4. Other Therapies

8.1.4.1. Market Revenue and Forecast

Chapter 9. Global Gene Therapy Market, By Vector

9.1. Gene Therapy Market, by Vector

9.1.1. Viral Vectors

9.1.1.1. Market Revenue and Forecast

9.1.2. Non-Viral Vectors

9.1.2.1. Market Revenue and Forecast

Chapter 10. Global Gene Therapy Market, By Therapeutic Area 

10.1. Gene Therapy Market, by Therapeutic Area

10.1.1. Neurology

10.1.1.1. Market Revenue and Forecast

10.1.2. Oncology

10.1.2.1. Market Revenue and Forecast

10.1.3. Hepatology

10.1.3.1. Market Revenue and Forecast

10.1.4. Other Therapeutic Areas

10.1.4.1. Market Revenue and Forecast

Chapter 11. Global Gene Therapy Market, By Delivery Method

11.1. Gene Therapy Market, by Delivery Method

11.1.1. In Vivo

11.1.1.1. Market Revenue and Forecast

11.1.2. Ex Vivo

11.1.2.1. Market Revenue and Forecast

Chapter 12. Global Gene Therapy Market, By Route of Administration

12.1. Gene Therapy Market, by Route of Administration

12.1.1. Intravenous

12.1.1.1. Market Revenue and Forecast

12.1.2. Other

12.1.2.1. Market Revenue and Forecast

Chapter 13. Global Gene Therapy Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Type

13.1.2. Market Revenue and Forecast, by Vector

13.1.3. Market Revenue and Forecast, by Therapeutic Area

13.1.4. Market Revenue and Forecast, by Delivery Method

13.1.5. Market Revenue and Forecast, by Route of Administration

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Type

13.1.6.2. Market Revenue and Forecast, by Vector

13.1.6.3. Market Revenue and Forecast, by Therapeutic Area

13.1.6.4. Market Revenue and Forecast, by Delivery Method

13.1.6.5. Market Revenue and Forecast, by Route of Administration 

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Forecast, by Type

13.1.7.2. Market Revenue and Forecast, by Vector

13.1.7.3. Market Revenue and Forecast, by Therapeutic Area

13.1.7.4. Market Revenue and Forecast, by Delivery Method

13.1.7.5. Market Revenue and Forecast, by Route of Administration

13.2. Europe

13.2.1. Market Revenue and Forecast, by Type

13.2.2. Market Revenue and Forecast, by Vector

13.2.3. Market Revenue and Forecast, by Therapeutic Area

13.2.4. Market Revenue and Forecast, by Delivery Method 

13.2.5. Market Revenue and Forecast, by Route of Administration 

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Type

13.2.6.2. Market Revenue and Forecast, by Vector

13.2.6.3. Market Revenue and Forecast, by Therapeutic Area

13.2.7. Market Revenue and Forecast, by Delivery Method 

13.2.8. Market Revenue and Forecast, by Route of Administration 

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Type

13.2.9.2. Market Revenue and Forecast, by Vector

13.2.9.3. Market Revenue and Forecast, by Therapeutic Area

13.2.10. Market Revenue and Forecast, by Delivery Method

13.2.11. Market Revenue and Forecast, by Route of Administration

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Type

13.2.12.2. Market Revenue and Forecast, by Vector

13.2.12.3. Market Revenue and Forecast, by Therapeutic Area

13.2.12.4. Market Revenue and Forecast, by Delivery Method

13.2.13. Market Revenue and Forecast, by Route of Administration

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Type

13.2.14.2. Market Revenue and Forecast, by Vector

13.2.14.3. Market Revenue and Forecast, by Therapeutic Area

13.2.14.4. Market Revenue and Forecast, by Delivery Method

13.2.15. Market Revenue and Forecast, by Route of Administration

13.3. APAC

13.3.1. Market Revenue and Forecast, by Type

13.3.2. Market Revenue and Forecast, by Vector

13.3.3. Market Revenue and Forecast, by Therapeutic Area

13.3.4. Market Revenue and Forecast, by Delivery Method

13.3.5. Market Revenue and Forecast, by Route of Administration

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Type

13.3.6.2. Market Revenue and Forecast, by Vector

13.3.6.3. Market Revenue and Forecast, by Therapeutic Area

13.3.6.4. Market Revenue and Forecast, by Delivery Method

13.3.7. Market Revenue and Forecast, by Route of Administration

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Type

13.3.8.2. Market Revenue and Forecast, by Vector

13.3.8.3. Market Revenue and Forecast, by Therapeutic Area

13.3.8.4. Market Revenue and Forecast, by Delivery Method

13.3.9. Market Revenue and Forecast, by Route of Administration

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Type

13.3.10.2. Market Revenue and Forecast, by Vector

13.3.10.3. Market Revenue and Forecast, by Therapeutic Area

13.3.10.4. Market Revenue and Forecast, by Delivery Method

13.3.10.5. Market Revenue and Forecast, by Route of Administration

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Type

13.3.11.2. Market Revenue and Forecast, by Vector

13.3.11.3. Market Revenue and Forecast, by Therapeutic Area

13.3.11.4. Market Revenue and Forecast, by Delivery Method

13.3.11.5. Market Revenue and Forecast, by Route of Administration

13.4. MEA

13.4.1. Market Revenue and Forecast, by Type

13.4.2. Market Revenue and Forecast, by Vector

13.4.3. Market Revenue and Forecast, by Therapeutic Area

13.4.4. Market Revenue and Forecast, by Delivery Method

13.4.5. Market Revenue and Forecast, by Route of Administration

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Type

13.4.6.2. Market Revenue and Forecast, by Vector

13.4.6.3. Market Revenue and Forecast, by Therapeutic Area

13.4.6.4. Market Revenue and Forecast, by Delivery Method

13.4.7. Market Revenue and Forecast, by Route of Administration

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Type

13.4.8.2. Market Revenue and Forecast, by Vector

13.4.8.3. Market Revenue and Forecast, by Therapeutic Area

13.4.8.4. Market Revenue and Forecast, by Delivery Method

13.4.9. Market Revenue and Forecast, by Route of Administration

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Type

13.4.10.2. Market Revenue and Forecast, by Vector

13.4.10.3. Market Revenue and Forecast, by Therapeutic Area

13.4.10.4. Market Revenue and Forecast, by Delivery Method

13.4.10.5. Market Revenue and Forecast, by Route of Administration

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Type

13.4.11.2. Market Revenue and Forecast, by Vector

13.4.11.3. Market Revenue and Forecast, by Therapeutic Area

13.4.11.4. Market Revenue and Forecast, by Delivery Method

13.4.11.5. Market Revenue and Forecast, by Route of Administration

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Type

13.5.2. Market Revenue and Forecast, by Vector

13.5.3. Market Revenue and Forecast, by Therapeutic Area

13.5.4. Market Revenue and Forecast, by Delivery Method

13.5.5. Market Revenue and Forecast, by Route of Administration

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Type

13.5.6.2. Market Revenue and Forecast, by Vector

13.5.6.3. Market Revenue and Forecast, by Therapeutic Area

13.5.6.4. Market Revenue and Forecast, by Delivery Method

13.5.7. Market Revenue and Forecast, by Route of Administration

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Type

13.5.8.2. Market Revenue and Forecast, by Vector

13.5.8.3. Market Revenue and Forecast, by Therapeutic Area

13.5.8.4. Market Revenue and Forecast, by Delivery Method

13.5.8.5. Market Revenue and Forecast, by Route of Administration

Chapter 14. Company Profiles

14.1. Dimension Therapeutics Inc.

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Taxus Cardium Pharmaceuticals Group Inc.

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Taxus Cardium Pharmaceuticals Group Inc.

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Shanghai Sunway Biotech Co. Ltd

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Applied Genetic Technologies Corporation

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Applied Genetic Technologies Corporation

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. American Gene Technologies

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. BioMarin Pharmaceuticals Inc.

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Gensight Biologics S.A.

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Sibinono GeneTech Co. Ltd

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

According to Precedence Research, the global gene therapy market was valued at USD 9.26 billion in 2024 and is predicted to reach over USD 55.43 billion by 2034.

The global gene therapy market is expected to registered growth at a CAGR of 19.60% from 2025 to 2034.

The growing field of advanced therapeutics and gene delivery technologies has generated a competitive environment in which a large number of market companies are working to commercialize their gene therapy products.

The major players operating in the gene therapy market are Dimension Therapeutics Inc., Taxus Cardium Pharmaceuticals Group Inc., Epeius Biotechnologies Corp., Shanghai Sunway Biotech Co. Ltd, Applied Genetic Technologies Corporation, Bristol-Myers Squibb Company, American Gene Technologies, BioMarin Pharmaceuticals Inc., Gensight Biologics S.A., Sibinono GeneTech Co. Ltd.

North america region will lead the global gene therapy market in near future.

The applications of gene therapy market are oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious diseases, and others.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client